Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Invivo Therapeutics Holdings Corp    NVIV

INVIVO THERAPEUTICS HOLDINGS CORP

(NVIV)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

InVivo Therapeutics : Announces Postponement of Annual Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/15/2019 | 09:30am EDT

CAMBRIDGE - InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that it has postponed its 2019 annual meeting of stockholders.

The annual meeting, which was originally scheduled for June 11, 2019, had been adjourned until July 11, 2019 at 8:00 am Eastern Time. Less than a majority of the shares of the Company's outstanding common stock entitled to vote at the meeting were present in person or by proxy on July 11, 2019, and the Company therefore determined that a quorum did not exist. The Company anticipates publicly announcing a new record date and the new date, time and location of the annual meeting later in 2019.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children's Hospital and who now is affiliated with Massachusetts General Hospital. The publicly traded company is headquartered in Cambridge, MA.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as 'believe,' 'anticipate,' 'intend,' 'estimate,' 'will,' 'may,' 'should,' 'expect' and similar expressions, and include statements regarding the expectations related to the announcement of a new annual meeting record date and new date, time and location of the meeting. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the Company's ability to obtain FDA approval to commercialize its products; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization and other risks associated with the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, and its other filings with the SEC, including the Company's Form 10-K, Form 10-Qs and current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.

Contact:

Bret Shapiro

Tel: (516) 222-2560

Email: brets@coreir.com

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INVIVO THERAPEUTICS HOLDIN
08/13INVIVO THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
07/19INVIVO THERAPEUTICS HOLDINGS CORP. : Notice of Delisting or Failure to Satisfy a..
AQ
07/16INVIVO THERAPEUTICS : Announces Publication of CONTEMPO Registry Study Data in P..
BU
07/15INVIVO THERAPEUTICS : Announces Postponement of Annual Meeting
AQ
07/12INVIVO THERAPEUTICS HOLDINGS CORP. : Other Events, Financial Statements and Exhi..
AQ
07/12INVIVO THERAPEUTICS : Announces Postponement of Annual Meeting
BU
07/05INVIVO THERAPEUTICS HOLDINGS CORP. : Other Events (form 8-K)
AQ
06/14INVIVO THERAPEUTICS HOLDINGS CORP. : Submission of Matters to a Vote of Security..
AQ
06/14INVIVO THERAPEUTICS : Announces Adjournment of Annual Meeting
BU
05/29INVIVO THERAPEUTICS : Announces Enrollment of First Two Patients into the INSPIR..
BU
More news
Financials (USD)
Sales 2019 -
EBIT 2019 -12,6 M
Net income 2019 -12,2 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -0,46x
P/E ratio 2020 -0,75x
Capi. / Sales2019 infx
Capi. / Sales2020 infx
Capitalization 5,31 M
Chart INVIVO THERAPEUTICS HOLDINGS CORP
Duration : Period :
Invivo Therapeutics Holdings Corp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVIVO THERAPEUTICS HOLDIN
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 4,60  $
Last Close Price 0,57  $
Spread / Highest target 707%
Spread / Average Target 707%
Spread / Lowest Target 707%
EPS Revisions
Managers
NameTitle
Richard Toselli President, Chief Executive Officer & Director
C. Ann Merrifield Chairman
William D'Agostino Senior Vice President-Operations
Richard C. Christopher Chief Financial Officer & Treasurer
Richard John Roberts Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INVIVO THERAPEUTICS HOLDINGS CORP-62.25%5
THERMO FISHER SCIENTIFIC32.41%118 673
DANAHER CORPORATION42.04%105 073
INTUITIVE SURGICAL10.91%61 218
BOSTON SCIENTIFIC CORPORATION22.50%60 302
EDWARDS LIFESCIENCES CORPORATION43.41%45 683